Abstract:BackgroundSince China has a unique system of delivering HIV care that includes all patients' records. The factors related to CD4+ T-cell recovery and viral suppression in patients who have low CD4+ T cell counts at the initiation of HAART are understudied in the China despite subsequent virological suppression (viral load < 50 copies/mL) is unknown.MethodsThe authors conducted a retrospective cohort study using data from the national HIV treatment sub-database of Zhejiang province to identify records of HIV+ patients. Patient records were included if they were < 16 years of age, had an initial CD4 count < 100 cells/mu L, were on continuous HAART for at least one year by the end of December 31, 2014; and achieved and maintained continued maximum virological suppression (MVS) (< 50 copies/ml) by 9 months after starting HAART. The primary endpoint for analysis was time to first CD4+ T cell count recovery (>= 200, 350, 500 cells/mu L). Cox proportional hazard regression was used to identify the risk factors for CD4+ T cell count recovery to key thresholds (200350, 350-500, >= 00 cells/mu L) by the time of last clinical follow-up (whichever occurred first), key thresholds (follow-up date for analysis), with patients still unable to reach the end-points being censored by the end December 31, 2014 (follow-up date for analysis).ResultsOf the 918 patients who were included in the study, and the median CD4+ T cell count was 39 cells/mu L at the baseline. At the end of follow-up, 727 (79.2%), 363 (39.5%) and 149 (16.2%) patients had return to >= 200, 350, and 500 cells/mu L, respectively. Kaplan-Meier analysis demonstrated that the rate of patients with CD4+ count recovery to >= 200, 350, and 500 cells/mu L after 1 year on HAART was 43.6, 8.6, and 2.5%, respectively, after 3 years on treatment was 90.8, 46.3, and 17.9%, respectively, and after 5 years on HAART was 97.1, 72.2, and 36.4%, respectively. The median time to return to 200-350, 350-500, >= 500cells/mu L was 1.11, 3.33 and 6.91 years, respectively. Factors of age (aHR = 0.77, 95% CI 0.61-0.97), baseline CD4+ count (aHR = 1.60, 95% CI 1.37-1.86), initial regimens, changes in regimen (aHR = 0.58, 95% CI 0.49-0.69), and inclusion of a cotrimoxazole prophylaxis (aHR = 0.66, 95% CI 0.51-0.85) were associated with CD4+ T cell count recovery.ConclusionThe proportion of patients with initially low CD4 counts after nine months of treatment and that achieved continuous virological suppression was greater than 70% for persons with CD4+ count >= 350. Conversely, only 35% of patients recovered to levels of 500 cells/mu L after 5 years of treatment, and levels continued to rise significantly with further long-term HAART. Early HAART intervention will be necessary for achieving effective CD4+ T cell responses and optimal immunological function in HIV+ patients.

H∞ control of singularly perturbed systems with multiple delays

Global trends in CD4 count measurement and distribution at first antiretroviral treatment initiation

Trends in Baseline CD4 Cell Counts and Risk Factors for Late Antiretroviral Therapy Initiation among HIV-positive Patients in Shanghai, a Retrospective Cross-Sectional Study.

CD4+ cell dynamics in untreated HIV-1 infection: overall rates, and effects of age, viral load, sex and calendar time

Evolution of CD4 T-Cell Count With Age in a Cohort of Young People Growing Up With Perinatally Acquired Human Immunodeficiency Virus

Trends in Clinical Characteristics of HIV-infected Patients Initiating Antiretroviral Therapy in Shanghai from 2006 to 2011.

Anti-retroviral therapy for HIV: who should we test and who should we treat?

Impact of increasing CD4 count threshold eligibility for antiretroviral therapy initiation on advanced HIV disease and tuberculosis prevalence and incidence in South Africa: an interrupted time series analysis

The Factors Related To Cd4+T-Cell Recovery And Viral Suppression In Patients Who Have Low Cd4+T Cell Counts At The Initiation Of Haart: A Retrospective Study Of The National Hiv Treatment Sub-Database Of Zhejiang Province, China, 2014

Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.

CD4 Count at Entry into Care and at Antiretroviral Therapy Prescription among Adults with Human Immunodeficiency Virus in the United States, 2005-2018

Effects of high CD4 cell counts on death and attrition among HIV patients receiving antiretroviral treatment: an observational cohort study

Diagnostic accuracy of CD4 cell count increase for virologic response after initiating highly active antiretroviral therapy

HIV, TB and ART: the CD4 enigma

The surgical treatment of spasmodic torticollis

Effect of the timing of antiretroviral treatment initiation on CD4 count in children and youths living with HIV in North India

Impact of antiretroviral therapy during acute or early HIV infection on virologic and immunologic outcomes: results from a multinational clinical trial

Trends and the associated factors of optimal immunological response and virological response in late anti-retroviral therapy initiation HIV cases in Taiwan from 2009 to 2020

Presidential address: word fallout: or, on the hazards of explanation.

Current status and influencing factors of different initiation time of antiretroviral therapy in HIV/AIDS patients

Delayed Treatment for People Living with HIV in China, 2004-2016: An Analysis of An Observational Cohort